![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/f42cf5e88e95cf3ad2098e209fd9cf1ea8f9c5d8-1920x1080.png?fit=crop&auto=format)
BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel
BlueRock Therapeutics’ bemdaneprocel (also known as MSK-DA01 and BRT-DA01), an investigational neuronal cell therapy, is currently being evaluated for the treatment of Parkinson disease (PD) in a phase 1 clinical trial (NCT04802733).1 In honor of World …